

IDT has steadily grown over the past 15 years, to support this growth Wilkore has built a number of projects for them, including IDT's Head Office as well as other laboratories and facilities as noted below:

- Facility 'B' – 250L Antineoplastic Manufacturing Facility
- Facility 'K' – Platinum Products Manufacturing Facility
- Facility 'L' – Cytotoxic Manufacturing Research Facility
- Facility 'R' – Cytotoxic Research and Development Facility
- Facility 'V' – Viral Containment Facility
- Facility 'F8' – Research and Development Facility
- Facility 'N' – Cytotoxic Testing Facility
- Facility 'E' – Critical Containment Manufacturing Facility
- Facility 'F4' – Critical Containment Laboratory

The majority of these facilities are designed to contain viruses, cytotoxic or highly potent materials. All critical containment rooms have HEPA filtered supply and return air and operate at a negative pressure to atmosphere, serviced by positive pressure airlocks.

In addition, the manufacturing facilities must operate under GMP conditions. As many of the materials are parenteral products, the facilities must operate under Class 3500 as a minimum with some facilities at Class 350. The facilities are fully validated and several facilities have been inspected by the FDA.

CLIENT

Institute of Drug Technologies

PROJECT VALUE

\$6.3M

LOCATION

Knoxfield, VIC

REFEREE

John Thornborrow, Bruce Hearn

